Merck & Co Inc (MRK) Stock Price, Trades & News

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. In cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 53% of the company's 2025 sales were generated from US human health (pharmaceuticals and vaccines).

Financial Strength

5/10

Name	Current	Vs Industry
Cash-To-Debt	0.13
Equity-to-Asset	0.32
Debt-to-Equity	1.29
Debt-to-EBITDA	3.74
Interest Coverage	4.01
Piotroski F-Score	5/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	4.04	Distress Grey Safe
Beneish M-Score	-3.07	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

7/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	3.6
	3-Year EBITDA Growth Rate	10.4
	3-Year EPS without NRI Growth Rate	6.3
	3-Year FCF Growth Rate	-5.2
	3-Year Book Growth Rate	5.5
	Future 3-5Y Total Revenue Growth Rate Estimate	4.76

Momentum Rank

1/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	94.91
	9-Day RSI	89.59
	14-Day RSI	83.13
	3-1 Month Momentum %	10.09
	6-1 Month Momentum %	1.75
	12-1 Month Momentum %	46.94

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	1.32
	Quick Ratio	1.1
	Cash Ratio	0.26
	Days Inventory	131.38
	Days Sales Outstanding	66.36
	Days Payable	81.67

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	Dividend Yield %	2.25
	Dividend Payout Ratio	1.05
	3-Year Dividend Growth Rate	5.4
	Forward Dividend Yield %	2.27
	5-Year Yield-on-Cost %	2.97
	3-Year Average Share Buyback Ratio	0.8
	Shareholder Yield %	0.14

Profitability Rank

8/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	72.97
	Operating Margin %	10.49
	Net Margin %	4.77
	EBITDA Margin %	21.64
	FCF Margin %	24.13
	OCF Margin %	29.99
	ROE %	6.58
	ROA %	2.47
	ROIC %	4.03
	3-Year ROIIC %	14.23
	ROC (Joel Greenblatt) %	26.34
	ROCE %	7.62
	Years of Profitability over Past 10-Year	10
	Moat Score	8
	Tariff Resilience Score	7

GF Value Rank

5/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	119.19
	Forward PE Ratio	54.24
	PE Ratio without NRI	46.41
	Shiller PE Ratio	37.34
	Price-to-Owner-Earnings	139.23
	PEG Ratio	2.94
	PS Ratio	5.57
	PB Ratio	8.77
	Price-to-Free-Cash-Flow	23.05
	Price-to-Operating-Cash-Flow	18.55
	EV-to-EBIT	53.89
	EV-to-Forward-EBIT	39.58
	EV-to-EBITDA	28.77
	EV-to-Forward-EBITDA	26.43
	EV-to-Revenue	6.23
	EV-to-Forward-Revenue	6.28
	EV-to-FCF	25.8
	Price-to-GF-Value	1.24
	Price-to-Projected-FCF	2.22
	Price-to-Median-PS-Value	1.24
	Price-to-Peter-Lynch-Fair-Value	4.48
	Earnings Yield (Greenblatt) %	1.86
	FCF Yield %	4.37
	Forward Rate of Return (Yacktman) %	13.87

Financials (Next Earnings Date:2026-10-29)

Annual Quarterly TTM

MRK's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Gurus Latest Trades with NYSE:MRK

No Available Data

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

Merck & Co Inc Executives

Details

GF Value™: $119.88

MRK

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 7 Medium warning signs with MRK. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil $)	66,569
	EPS (TTM) ($)	1.25
	Beta	-0.0212
	3-Year Sharpe Ratio	0.21
	3-Year Sortino Ratio	0.36
	Volatility %	27.29
	14-Day RSI	83.13
	14-Day ATR ($)	4.316605
	20-Day SMA ($)	132.226
	12-1 Month Momentum %	46.94
	52-Week Range ($)	77.58 - 153.5
	Shares Outstanding (Mil)	2,467.17

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	5
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Merck & Co Inc Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Merck & Co Inc Stock Events

Financials Calendars

Event	Date	Price ($)
Fourth quarter earnings conference call for 2026	2027-02-02 09:00	In 166 days
Fourth quarter earnings results for 2026	2027-02-02	In 165 days
Third quarter earnings conference call for 2026	2026-10-29	In 69 days
Third quarter earnings results for 2026	2026-10-29	In 69 days
USD 0.850000 Cash Dividend	2026-09-15	In 25 days
Second quarter earnings conference call for 2026	2026-08-04 09:00	127.77 (-1.62%)
Second quarter earnings results for 2026	2026-08-04	127.77 (-1.62%)
USD 0.850000 Cash Dividend	2026-06-15	119.05 (-2.02%)
Goldman Sachs 47th Annual Global Healthcare Conference	2026-06-09 11:20	119.52 (-1.10%)
Jefferies Global Healthcare Conference in New York	2026-06-04 10:30	114.70 (-0.65%)

Show

Entries

Merck & Co Inc Frequently Asked Questions

What is Merck & Co Inc(MRK)'s stock price today?

The current price of MRK is $148.99. The 52 week high of MRK is $153.50 and 52 week low is $77.58.

When is next earnings date of Merck & Co Inc(MRK)?

The next earnings date of Merck & Co Inc(MRK) is 2026-10-29.

Does Merck & Co Inc(MRK) pay dividends? If so, how much?

The Dividend Yield % of Merck & Co Inc(MRK) is 2.25% (As of Today), Highest Dividend Payout Ratio of Merck & Co Inc(MRK) was 1.96. The lowest was 0.37. And the median was 0.47. The Forward Dividend Yield % of Merck & Co Inc(MRK) is 2.27%. For more information regarding to dividend, please check our Dividend Page.

Guru Commentaries on NYSE:MRK

No fund manager commentary yet.

Browse all fund letters →

Press Release

	Subject	Date
	Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients Wit	2026-08-19
	U.S. FDA Accepts sBLA for ENFLONSIA™ (clesrovimab-cfor) to Update its Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease Indication to Include Children Under Two Years at Increased Risk	2026-08-06
	Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2026 Financial Results; Highlights Key Regulatory and Clinical Milestones Across Broad, Diverse Pipeline	2026-08-04
	Merck Announces Fourth-Quarter 2026 Dividend	2026-07-29
	Merck Announces Initial Access Plans for Alimatravir, an Investigational Once-Monthly Oral HIV Pre-Exposure Prophylaxis in Phase 3 Development	2026-07-24
	Merck's LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia	2026-07-16
	Merck to Present New Data on Daily, Weekly, and Monthly Options Across its HIV Treatment and Prevention Pipeline at AIDS 2026	2026-07-15
	KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR)	2026-07-15
	FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults	2026-07-10
	Merck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4	2026-07-01

10/Page

Articles on Merck & Co Inc

AMZN

Market Today: Walmart Drops, Moderna & Merck Rally, Charter-Cox Merger

3 hours ago

MRK

Merck Slips After 12.6% Cancer-Vaccine Surge

6 hours ago

AMZN

First Look: Walmart, Meta, Target, and Fed News Move Markets

12 hours ago

MRK

MRK Looks 27.0% Overvalued on GF Value™ Amid Dividend Sustainability Concerns

13 hours ago

AMZN

Market Today: Moderna, Target, Amazon, Nike Lead Major Market Moves

1 day ago

Headlines

Aug 20, 2026

SA analyst upgrades/downgrades: AVGO, MRK, HPE, WULF

Seeking Alpha • 12:47pm

Moderna breakthrough: The options lottery tickets that paid out

Seeking Alpha • 3:58am

Moderna nearly triples in record S&P 500 move, but analyst sees more volatility ahead

Seeking Alpha • 3:17am

Aug 19, 2026

Biotechs hit a post-pandemic high after mRNA trial win for Moderna, Merck

Seeking Alpha • 1:38pm

New CDC director says vaccines are 'safe and effective'

Seeking Alpha • 1:38pm

Trump nominates White House adviser Overton as next FDA commissioner

Seeking Alpha • 11:19am

BioNTech’s rally on Moderna trial win likely to fade, Leerink says

Seeking Alpha • 11:08am

Moderna surges on trial win for cancer shot; William Blair upgrades

Seeking Alpha • 9:09am

Biggest stock movers Wednesday: SKHY, MRNA, MRVL, and more

Seeking Alpha • 8:42am

4 stocks to watch on Wednesday: MRK, TGT, MRVL, and DUOL

Seeking Alpha • 7:55am

At a glance: stocks gapping up premarket

Seeking Alpha • 7:12am

Trump expected to nominate White House aide Heidi Overton as FDA commissioner

Seeking Alpha • 12:26am

Aug 18, 2026

President boasts of drug savings with Most Favored Nation policy, TrumpRx

Seeking Alpha • 1:47pm

Aug 15, 2026

Notable trades: Netflix, Coca-Cola, Pfizer among notable names

Seeking Alpha • 10:00am

Aug 13, 2026

Splitting the MMR vaccine? Experts warn it could take a decade

Seeking Alpha • 4:16am

Aug 12, 2026

U.K. regulator reaffirms safety of childhood vaccination

Seeking Alpha • 8:13am

Aug 10, 2026

Trump executive order set to make major changes to childhood vaccines schedule

Seeking Alpha • 1:59pm

Aug 08, 2026

Earnings Scorecard: 95% of healthcare firms deliver EPS wins this week

Seeking Alpha • 10:15am

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.